SCHEMBL956796

SCHEMBL956796

O=C(O)Cc1cccc(OCc2ccc(C(F)(F)F)cc2C(F)(F)F)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 4/20 0.55
NR1H3 Q13133 4/20 0.55
RXRA P19793 4/20 0.55
MRGPRX4 Q96LA9 2/20 0.52
NR4A2 P43354 2/20 0.52
PPARD Q03181 5/20 0.49
PPARA Q07869 4/20 0.49
PPARG P37231 3/20 0.49
DDR1 Q08345 1/20 0.48
MAOB P27338 2/20 0.48
RXRB P28702 1/20 0.47
RXRG P48443 1/20 0.47
FFAR1 O14842 1/20 0.47
FFAR4 Q5NUL3 1/20 0.47
SRD5A2 P31213 1/20 0.46
MEN1 O00255 1/20 0.46
NR1I2 O75469 1/20 0.46
ALDH1A1 P00352 1/20 0.46
MAPT P10636 1/20 0.46
VHL P40337 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6242006 0.86 RXRA (0.63) NR1H2NR1H3RXRAPPARDPPARA
SCHEMBL3079913 0.85 MAOB (0.47) NR1H2NR1H3RXRAMRGPRX4NR4A2
SCHEMBL1010424 0.84 MAOB (0.64) RXRAMRGPRX4NR4A2PPARDPPARA
SCHEMBL6088493 0.78 MRGPRX4 (0.50) NR1H2NR1H3RXRAMRGPRX4NR4A2
SCHEMBL5580868 0.77 MAOB (0.59) NR1H2NR1H3RXRAMRGPRX4NR4A2
SCHEMBL5870447 0.77 TP53 (0.46) NR1H2NR1H3RXRAMRGPRX4NR4A2
SCHEMBL6242372 0.77 SRD5A2 (0.68) NR1H2NR1H3RXRAPPARDPPARA
SCHEMBL18001514 0.77 NPC1 (0.52) MAOBALDH1A1MAPT
SCHEMBL14987264 0.76 PPARD (0.50) NR1H2NR1H3RXRAMRGPRX4NR4A2
SCHEMBL6239593 0.76 SRD5A2 (0.75) NR1H2NR1H3RXRAMRGPRX4NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP claimed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US claimed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US claimed
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2011-01-20 US claimed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP claimed
US-20100234464-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2010-09-16 US claimed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO claimed
EP-2026659-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2009-02-25 EP claimed
WO-2007146768-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-21 WO claimed
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-8829058-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2014-09-09 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
EP-2026659-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2009-02-25 EP disclosed
EP-2026659-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Wellstat Therapeutics Corporation (US) 2009-02-25 EP disclosed
WO-2007146768-A3 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORP (US) 2008-02-21 WO disclosed
WO-2007146768-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-21 WO disclosed
WO-2007146768-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-21 WO disclosed
WO-2007146768-A2 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS WELLSTAT THERAPEUTICS CORPORATION (US) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234464-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PC, GOT2, OAT NR1H2 332/4885NR1H3 251/4885RXRA 867/4885
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 NR1H2 98/4885NR1H3 83/4885RXRA 603/4885
US-20110014176-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID UGP2, TAS2R46, PYCARD NR1H2 809/4885NR1H3 860/4885RXRA 951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.